Scientists in Japan say a pill could one day replace many insulin shots, and the new research points to a peptide carrier that helps insulin cross the gut. The team built a peptide called DNP-V to escort insulin through the small intestine, tested versions with zinc-stabilized insulin, and reported strong glucose-lowering effects in diabetic mice. The work, published in Molecular Pharmaceutics out of Kumamoto University, suggests a possible path toward oral delivery of biologic drugs that are normally injected.
Researchers developed a carrier peptide named DNP-V to get insulin across the intestinal wall, where large proteins usually fail to be absorbed. Their approach focused on two tactics: pairing the carrier peptide with zinc-stabilized insulin and chemically linking the peptide to insulin itself. Both strategies aimed to protect insulin and help it move through the small intestine for absorption.
In diabetic mouse models, a single oral dose produced a rapid fall in blood glucose and then a longer-lasting reduction that brought levels close to normal. The zinc-stabilized insulin formulation helped stabilize the hormone while DNP-V promoted intestinal uptake. The combination delivered both a quick and sustained glucose-lowering effect in those preclinical tests.
When the research team attached DNP-V directly to insulin, intestinal absorption improved and the glucose response was comparable to the mixed formulation. That direct conjugation suggests the peptide could be adapted to different drugs, not just insulin. It points to a flexible platform for turning injectable biologics into oral forms.
The treatment worked across several diabetes models and notably reduced blood sugar spikes after meals with just one dose per day. That kind of postprandial control is a big deal because meal-time glucose surges drive complications over time. If the effect translates to humans, it could change daily routines for many people who now rely on multiple injections.
Study authors framed the work as a platform for oral biopharmaceuticals and highlighted the patient implications. “This technology can simply and effectively convert injectable biopharmaceuticals into orally administrable forms, offering a promising path to practical, patient-friendly oral therapies,” they wrote. The language signals an eye toward usability, not just lab success.
The team cautioned that results in mice do not guarantee the same outcomes in people and that further research is needed before human trials. Translating dosing, stability, and safety from rodents to humans remains a major hurdle for any oral peptide strategy. Still, the preclinical findings are a clear proof of concept that merits more work.
Dr. Marc Siegel, who was not involved in the study, weighed in on the potential. “Insulin use, especially in type 1 diabetes, is sometimes difficult to regulate by injection,” he said. “Oral use would have major advantages.” He added, “This is very promising provided that it works in humans, which is a big ‘if.'”
Other clinicians also flagged both promise and limits. “If these findings are confirmed in humans, the approach could reduce injection burden, improve adherence, and potentially help lower complication risk in patients with type 1 diabetes and insulin-requiring type 2 diabetes,” said Dr. Philip Rabito. That captures the main patient-level benefits researchers hope to achieve.
Dr. Peter Balazs urged caution and clarified what oral insulin would and would not do. “For type 1 diabetes, this approach would not eliminate the need for injections entirely, as basal insulin would still likely be required,” he said. He also noted these advances focus on “improving insulin delivery methods” rather than restoring pancreatic function and warned that dosing for oral insulin is “highly variable” compared to injections, meaning the same dose could act differently from day to day.
